Back to search results

Rowing Exercise for Breast Cancer Survivors

This study is looking at whether a supervised exercise program, specifically rowing, can help breast cancer survivors improve their heart health after chemotherapy. Researchers want to see if this exercise training can reduce the risk of heart problems, which can be higher for survivors due to past treatments. You might be able to join if you are a woman between 40 and 80 years old, have had stages I-III breast cancer, and completed your treatment 6 to 24 months ago. The study will measure changes in your blood vessel function (brachial FMD) and heart function (global longitudinal strain) after 12 weeks of exercise to see if the intervention is successful. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 72 women. It is a single-site, supervised exercise intervention.
What's involved
You would participate in a 12-week supervised exercise training program. Measurements of your heart and blood vessel function would be taken at the beginning and after 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Measurements are taken at baseline and following 12 weeks of supervised exercise training. The record does not specify follow-up beyond this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05848141

Rowing Following Breast Cancer Chemotherapy

Recruiting
NAAges 40–80InterventionalPrevention
University of Florida
~72 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Exercise training

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in brachial FMD
Measured over Baseline, Following 12 weeks of supervised exercise training
+5 more outcomes measured

Conditions

Breast Cancer Survivors

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Demetra Christou, PhD · PRINCIPAL_INVESTIGATOR · University of Florida

Who to contact

Demetra Christou, PhD
[email protected]
352-294-1746
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

diagnosis of primary invasive non-metastatic breast cancer, stages I-III
female based on biological sex
40 to 80 years of age
completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation
absence of contraindications to exercise or study participation
study clinician approval
receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation
lymphedema stage ≥ 2 prior to study enrolment
any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months

What this trial measures

  • Change in brachial FMDBaseline, Following 12 weeks of supervised exercise training

    Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia.

  • Change in global longitudinal strainBaseline, Following 12 weeks of supervised exercise training

    Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction.

  • % completed vs. planned exercise frequencyThroughout the 12 weeks of supervised exercise training

    We will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week.

  • % completed vs. planned exercise durationThroughout the 12 weeks of supervised exercise training

    We will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session.

  • % completed vs. planned exercise intensityThroughout the 12 weeks of supervised exercise training

    We will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session.

  • Number of participants who experience adverse event as defined by most recent CTCAEThroughout the 12 weeks of supervised exercise training

    To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions.